Oligonucleotides, inhibitors

Dean N, McKay R, Miraglia L, Howard R, Cooper S, Giddings ], Nicklin P, Meister L, Ziel R, Geiger T, Muller M, Fabbro D (19 ) Iidiibition of growth of human tumor cell lines in nude mice by an antisense oligonucleotide inhibitor of protein kinase C-a expression. Cancer Res 56 3499-3507 Defranco AL (1991) Immunosuppressants at work. Nature 352 754-755 De las Alas MM, Aebi S, Fink D, Howell SB, Los G (1997) Loss of DNA mismatch repair effects on the rate of mutation to drug resistance. J Natl Cancer Inst 89 1537-1541... 

Inhibitors of translation of viral mRNA (antisense oligonucleotides) Inhibitors of posttranslational glycosylation Antagonists of chemokine receptors... 

Miller, P.S. and Ts o, P O P. (1988) Oligonucleotide inhibitors of gene expression in living cells new opportunities in drug design. Ann. Reports Med. Chem., 23, 295-304. 

Yu RZ, Geary RS, Leeds JM, Watanabe T, Fitchett JR, Matson JE, Mehta R, Hardee GR, Templin MV, Huang K, Newman MS, Quinn Y, Uster P, Zhu G, Working PK, Homer M, Nelson J, Levin AA (1999) Pharmacokinetics and tissue disposition in monkeys of an antisense oligonucleotide inhibitor of Ha-ras encapsulated in stealth liposomes. Pharm Res 16(8) 1309—1315... 

D.K. Monteith, and A.A. Levin. 1997. Antisense oligonucleotide inhibitors for the treatment of cancer 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anti-Cancer Drug Design 12 383-393. 

McKay, R.A., L.J. Miraglia, L.L. Cummins, S.R. Owens, H. Sasmor, and N.M. Dean. 1999. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase... 

Jenison RD, Jennings SD, Walker DW, Bargatze RF, Oligonucleotide inhibitors of P-selectin-dependent neutrophil-platelet adhesion, Antisense Nucleic Acid Drug Dev, 8 265-279, 1998. 

Cooper, S.R. Taylor, J.K. Miraglia, L.J. Dean, N.M. Pharmacology of antisense oligonucleotide inhibitors of protein expression. Pharmacol. Ther. 1999, 82, 427-435. 

Rudin C M, HoImIund I, et al. (2001). Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin. Cancer Res. 7 1214-1220. 

Tasset, D. M., Kubik, M. F., Steiner, W. (1997). Oligonucleotide inhibitors of human thrombin that bind distinct epitopes. J Mol Biol 272, 688-698. 

Akhtar, S. et al. Sequence and chemistry requirements for a novel aptameric oligonucleotide inhibitor of EGF receptor tyrosine kinase activity, Biochem. Pharmacol, 63, 2187, 2002. 

Sawai, H Shibata, T., and Ohno, M. (1979) Synthesis of oligonucleotide inhibitor of protein synthesis pppA2 p5 A2 p5 A. Tetrahedron Lett. 47, 4573-4576. 

The binding at the active site of cyclic mono- and dinucleotide substrates or mono- and oligonucleotide inhibitors may be divided into at least four subsite interactions ... 

---